Both transient and stable transfections of miR-130b-3p oligonucleotide inhibitors in vitro and in vivo returned the miR-130b-3p-activated CAFs to a normal state, emphasizing the importance of the miR-130b-3p/SPIN90 axis for CAF activation and supporting the potential for this oligonucleotide to act as a therapeutic inhibitor of CAFs in breast cancer. This evidence concerns the gene NCKIPSD and breast carcinoma.